| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on November 25, 2003
Revised on April 20, 2004
Accepted on April 22, 2004
From the University of Pennsylvania, Philadelphia, Pa.
* To whom correspondence should be addressed. E-mail: rader{at}mail.med.upenn.edu.
Endothelial lipase (EL) has been found to be a key enzyme in high-density lipoprotein (HDL) metabolism in mice, leading to the concept that inhibition of EL could be a novel strategy for raising HDL cholesterol levels. However, mice are "HDL animals" and the effect of EL on atherogenic apoB-containing lipoproteins has not been elucidated. We previously found that EL is capable of hydrolyzing very low-density lipoprotein (VLDL) and LDL lipids ex vivo. To investigate the role of EL in the metabolism of apoB-containing lipoproteins in vivo, we expressed human EL in three mouse models of elevated apoB-containing lipoproteins: apoE-deficient, LDL receptor-deficient, and human apoB transgenic mice. Unexpectedly, hepatic expression of EL resulted in markedly decreased levels of VLDL/LDL cholesterol, phospholipid, and apoB accompanied by significantly increased LDL apolipoprotein and phospholipid catabolism. To determine whether lipolytic activity is required for this effect, we also expressed a catalytically inactive form of human EL (ELS149A); unexpectedly, expression of ELS149A did not lower and in fact increased plasma lipids. Coexpression and coimmunoprecipitation studies suggested that catalytically inactive ELS149A inhibits endogenous mouse EL, accounting for the increased lipid levels. We conclude that (1) in addition to its known effects on HDL metabolism, EL influences the metabolism of apoB-containing particles; (2) catalytic activity of EL is required for its effects on apoB-containing lipoproteins; and (3) overexpressed catalytically inactive EL inhibits endogenous mouse EL, resulting in increased levels of plasma lipids. In light of these results, inhibition of EL has the potential to raise levels of atherogenic lipoproteins in addition to HDL-C levels.
This article has been cited by other articles:
![]() |
M. K. Jensen, E. B. Rimm, K. J. Mukamal, A. C. Edmondson, D. J. Rader, U. Vogel, A. Tjonneland, T. I.A. Sorensen, E. B. Schmidt, and K. Overvad The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations Eur. Heart J., July 1, 2009; 30(13): 1584 - 1589. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Qiu and J. S. Hill Endothelial lipase enhances low density lipoprotein binding and cell association in THP-1 macrophages Cardiovasc Res, December 1, 2007; 76(3): 528 - 538. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Qiu and J. S. Hill Atorvastatin decreases lipoprotein lipase and endothelial lipase expression in human THP-1 macrophages J. Lipid Res., October 1, 2007; 48(10): 2112 - 2122. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Ahmed, G. Orasanu, V. Nehra, L. Asatryan, D. J. Rader, O. Ziouzenkova, and J. Plutzky High-Density Lipoprotein Hydrolysis by Endothelial Lipase Activates PPAR{alpha}: A Candidate Mechanism for High-Density Lipoprotein-Mediated Repression of Leukocyte Adhesion Circ. Res., March 3, 2006; 98(4): 490 - 498. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. S. Ko, A. Paul, K. Ma, L. Li, and L. Chan Endothelial lipase modulates HDL but has no effect on atherosclerosis development in apoE-/- and LDLR-/- mice J. Lipid Res., December 1, 2005; 46(12): 2586 - 2594. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Jin, I. V. Fuki, N. G. Seidah, S. Benjannet, J. M. Glick, and D. J. Rader Proprotein Covertases Are Responsible for Proteolysis and Inactivation of Endothelial Lipase J. Biol. Chem., November 4, 2005; 280(44): 36551 - 36559. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. S. Lindegaard, G. Olivecrona, C. Christoffersen, D. Kratky, J. Hannibal, B. L. Petersen, R. Zechner, P. Damm, and L. B. Nielsen Endothelial and lipoprotein lipases in human and mouse placenta J. Lipid Res., November 1, 2005; 46(11): 2339 - 2346. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Reilly, A. S. Foulkes, M. L. Wolfe, and D. J. Rader Higher order lipase gene association with plasma triglycerides J. Lipid Res., September 1, 2005; 46(9): 1914 - 1922. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. F. Lewis and D. J. Rader New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport Circ. Res., June 24, 2005; 96(12): 1221 - 1232. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shahmanesh, S. Das, M. Stolinski, F. Shojaee-Moradie, N. C. Jackson, W. Jefferson, R. Cramb, P. Nightingale, and A. M. Umpleby Antiretroviral Treatment Reduces Very-Low-Density Lipoprotein and Intermediate-Density Lipoprotein Apolipoprotein B Fractional Catabolic Rate in Human Immunodeficiency Virus-Infected Patients with Mild Dyslipidemia J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 755 - 760. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ishida, S. Y. Choi, R. K. Kundu, J. Spin, T. Yamashita, K.-i. Hirata, Y. Kojima, M. Yokoyama, A. D. Cooper, and T. Quertermous Endothelial Lipase Modulates Susceptibility to Atherosclerosis in Apolipoprotein-E-deficient Mice J. Biol. Chem., October 22, 2004; 279(43): 45085 - 45092. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |